Pharmaceuticals
Takeda chief says China’s drug development capabilities are approaching US standards
An Astellas Pharma office in Beijing. The company is preparing to open a new R&D facility in a Beijing industrial park. (Astellas Pharma)
TOKYO — Japanese pharmaceutical companies are increasing investment in China, the world’s second-largest market, as they seek to harness the country’s rapidly improving drug discovery capabilities and identify promising new treatment candidates.
